Afshin Dowlati

机构：University Hospitals of Cleveland, University Hospitals Seidman Cancer Center, Case Western Reserve University · ORCID：0000-0003-4535-6839

发表论文 719 篇 · 总被引 33210 次 · h-index 67

代表论文

First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6–Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non–Small Cell Lung Cancer (2026 · Journal of Clinical Oncology · 被引 2)
Roles of Restricted Mean Survival Time and Restricted Mean Time Lost in Evaluating Immune Checkpoint Inhibitor Efficacy for Extensive-Stage Small Cell Lung Cancer (2025 · Cancer Research Communications · 被引 1)
Figure 6: from Roles of Restricted Mean Survival Time and Restricted Mean Time Lost in Evaluating Immune Checkpoint Inhibitor Efficacy for Extensive-Stage Small Cell Lung Cancer (2026)
Figure 3: from Roles of Restricted Mean Survival Time and Restricted Mean Time Lost in Evaluating Immune Checkpoint Inhibitor Efficacy for Extensive-Stage Small Cell Lung Cancer (2026)
Figure 2: from Roles of Restricted Mean Survival Time and Restricted Mean Time Lost in Evaluating Immune Checkpoint Inhibitor Efficacy for Extensive-Stage Small Cell Lung Cancer (2026)
Figure 7: from Roles of Restricted Mean Survival Time and Restricted Mean Time Lost in Evaluating Immune Checkpoint Inhibitor Efficacy for Extensive-Stage Small Cell Lung Cancer (2026)